Harvard spinout Platelet BioGenesis has added $26m in series A1 financing to its coffers thanks to a consortium co-led by Ziff Capital Partners and Qiming Venture Partners USA.
Platelet BioGenesis (PBG), a US-based biotechnology spinout of Harvard University, today obtained $26m in a series A1 round co-led by Ziff Capital Partners and Qiming Venture Partners USA.
Nest.Bio Ventures and eCoast Angels also contributed to the round alongside other, unnamed backers.
Founded in 2014, PBG is working on pluripotent stem-cell derived human platelets and platelet-based treatments. Platelets are a part of the bloodstream and act as a natural form of a bandaid, being responsible for clot formation…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
